Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2000
10/24/2000CA2221148C Muscle trophic factor
10/24/2000CA2205530C Use of substituted aryl-morpholino-, thiomorpholino-or piperazino-propanones for the treatment of prevention of alzheimer's disease
10/24/2000CA2194226C Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
10/24/2000CA2181810C Process for producing s(+)-ibuprofen particles
10/24/2000CA2179628C Psoriasis treatment
10/24/2000CA2157247C Physical form of dihydro-2,3-benzodiazepine derivative
10/24/2000CA2137445C Naphtalene derivates, process for their preparation and pharmaceutical compositions containing them
10/24/2000CA2124814C 2'-deoxy-isoquanosines, isosteric analogues and isoquanosine derivatives as well as their use
10/24/2000CA2122930C Purified heparin fractions, method for obtaining them and pharmaceutical compositions containing them
10/24/2000CA2072283C Process for the preparation of diacetylrhein
10/24/2000CA2047702C Serpin resistant chymotrypsin superfamily proteases particularly pai-1 resistant t-pa, complementary inhibitor mutants; compositions; genes; expression
10/24/2000CA2024497C Chemical derivatives of antibiotics ll-f19020 alpha and beta
10/24/2000CA2021547C Pharmaceutically active 3-aryl and 3-heteroaryl-2-fluoro-1-olefins
10/24/2000CA2021316C Intraocular pressure reducing 11-acyl prostaglandins
10/22/2000CA2306337A1 Cosmetic compound, namely make-up compound, containing a pigment derived from pyrrolopyrrole
10/21/2000CA2268379A1 Inhibitor ligands directed against a receptor of vascular endothelial growth factor or against its coding sequence, as anti-angiogenics
10/19/2000WO2000062068A1 Method to type prion proteins
10/19/2000WO2000062067A1 Novel transduction molecules and methods for using same
10/19/2000WO2000062063A1 Methods for the diagnosis and treatment of metastatic prostate tumors
10/19/2000WO2000061788A2 Poly(dipeptide) as a drug carrier
10/19/2000WO2000061783A2 Process for preparing inhibitors of nucleoside metabolism
10/19/2000WO2000061779A1 49 human secreted proteins
10/19/2000WO2000061775A1 Synthesis of biologically active compounds in cells
10/19/2000WO2000061772A2 Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
10/19/2000WO2000061755A2 Secreted human proteins
10/19/2000WO2000061754A2 Human proteins and polynucleotides encoding them
10/19/2000WO2000061753A2 Compositions and methods for the treatment and diagnosis of breast cancer
10/19/2000WO2000061746A1 13 transmembrane protein expressed in prostate cancer
10/19/2000WO2000061742A2 Treatment of cardiac power failure using s100 proteins
10/19/2000WO2000061729A2 Regulation of the expression of transcriptional repressor genes using nucleic acid molecules
10/19/2000WO2000061628A1 49 human secreted proteins
10/19/2000WO2000061627A1 49 human secreted proteins
10/19/2000WO2000061623A1 62 human secreted proteins
10/19/2000WO2000061622A2 Genes associated with diseases of the kidney
10/19/2000WO2000061612A2 Compounds and methods for therapy and diagnosis of lung cancer
10/19/2000WO2000061604A2 Pharmaceutical compounds
10/19/2000WO2000061602A1 Antisense oligonucleotide modulation of stat3 expression
10/19/2000WO2000061597A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin
10/19/2000WO2000061596A1 50 human secreted proteins
10/19/2000WO2000061592A1 Monosulphates of 4 or 6 disaccharides
10/19/2000WO2000061590A1 Process for preparing amine platinum complexes
10/19/2000WO2000061587A1 Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines
10/19/2000WO2000061586A1 Bicyclic heteroaromatic compounds useful as lh agonists
10/19/2000WO2000061583A1 Xanthine derivatives and analogs as cell signaling inhibitors
10/19/2000WO2000061582A1 Substituted fused imidazole derivatives
10/19/2000WO2000061581A1 Amine derivatives
10/19/2000WO2000061580A1 Substituted bicyclic heteroaryl compounds as integrin antagonists
10/19/2000WO2000061579A1 New endothelin converting enzyme inhibitors, their production and their use
10/19/2000WO2000061578A1 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
10/19/2000WO2000061576A1 Triarylimidazoles
10/19/2000WO2000061571A1 4,5-diaryl-3(2h)-furanone derivatives as cyclooxygenase-2 inhibitors
10/19/2000WO2000061569A1 Adamantane derivatives
10/19/2000WO2000061568A2 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
10/19/2000WO2000061564A1 Antiviral pyrimidinedione derivatives and process for the preparation thereof
10/19/2000WO2000061563A1 Antiviral pyrimidinedione derivatives and process for the preparation thereof
10/19/2000WO2000061562A1 Neurotrophic substituted pyrimidines
10/19/2000WO2000061555A1 Indigoid bisindole derivatives
10/19/2000WO2000061552A1 N-SUBSTITUTED-N'-SUBSTITUTED UREA DERIVATIVE AND USE THEREOF AS TNF-α PRODUCTION INHIBITOR
10/19/2000WO2000061551A2 Pyrimidine-2-one derivatives as integrin receptor ligands
10/19/2000WO2000061550A1 Prostaglandin e1 derivatives
10/19/2000WO2000061549A2 Pharmaceutical compounds
10/19/2000WO2000061548A1 N-substituted-n'-substituted urea derivative and medicinal compositions containing the same
10/19/2000WO2000061546A2 Novel aryl-chloro-ethyl ureas
10/19/2000WO2000061543A2 Esters of l-carnitine or alkanoyl l-carnitines
10/19/2000WO2000061541A2 Pharmaceutical compounds
10/19/2000WO2000061539A1 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors
10/19/2000WO2000061537A2 Pharmaceutical compounds
10/19/2000WO2000061536A2 Synthesis and pharmaceuticals of novel 9-substituted-1,5-dichloroanthracene analogs
10/19/2000WO2000061234A1 Combinations of gaba analogs and tricyclic compounds to treat depression
10/19/2000WO2000061233A2 Methods and compositions for the treatment and prevention of lung disease involving a specific rar-gamma agonist
10/19/2000WO2000061232A2 Methods and compositions for the treatment and prevention of lung disease involving a specific rar-beta antagonist
10/19/2000WO2000061231A2 Medical use
10/19/2000WO2000061230A2 Estrogen receptors-beta antagonism and bone diseases
10/19/2000WO2000061191A2 Heat stable coated colloidal iron oxides
10/19/2000WO2000061189A2 Water-soluble compositions of bioactive lipophilic compounds
10/19/2000WO2000061188A1 Sodium channel blocker compositions and the use thereof
10/19/2000WO2000061185A1 Docetaxel in combination with rhumab her2 for the treatment of cancers
10/19/2000WO2000061180A2 Products and methods for treating ptp lar related diseases
10/19/2000WO2000061174A2 Use of pegylated interferon alpha for renal cell carcinoma treatment
10/19/2000WO2000061171A2 Uses of mammalian ox2 protein and related reagents
10/19/2000WO2000061167A2 TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-λB ACTIVITY INHIBITORS
10/19/2000WO2000061163A1 Plant preparation containing phenethylisothiocyanate
10/19/2000WO2000061162A1 Use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa
10/19/2000WO2000061159A1 MEDICAMENT FOR INHIBITING NF-λB
10/19/2000WO2000061153A1 Medicinal compositions and their method of preparation
10/19/2000WO2000061152A1 Management of pain after joint surgery
10/19/2000WO2000061151A2 Oligodeoxynucleotide and its use to induce an immune response
10/19/2000WO2000061150A1 Antisense modulation of fas mediated signaling
10/19/2000WO2000061148A1 Inhibitors for optic hypofunction caused by optic nerve cell injury induced by factors other than optic circulatory disorder
10/19/2000WO2000061147A1 Injectable naltrexone microsphere compositions and their use in reducing consumption of heroin and alcohol
10/19/2000WO2000061146A1 Camptothecin analogs and methods of preparation thereof
10/19/2000WO2000061145A1 Methods of inducing cancer cell death and tumor regression
10/19/2000WO2000061144A1 Method and means for preventing, treating, and diagnosing cardiovascular complications in patients with obstructive sleep apnea
10/19/2000WO2000061143A1 The use of alpha lipoic acid in the antimetastatic treatment
10/19/2000WO2000061142A1 Method and composition for the treatment of cancer
10/19/2000WO2000061141A2 Methods and compositions for enhancing delivery of therapeutic agents to tissues
10/19/2000WO2000061140A1 Anticonvulsant derivatives useful in maintaining weight loss
10/19/2000WO2000061139A1 Anticonvulsant derivatives useful in reducing blood glucose levels
10/19/2000WO2000061138A1 Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
10/19/2000WO2000061137A1 Anticonvulsant derivatives useful in lowering lipids
1 ... 6224 6225 6226 6227 6228 6229 6230 6231 6232 6233 6234 6235 6236 6237 6238 6239 6240 6241 6242 6243 6244 ... 7860